Antibiotic – nemonoxacin

Published: 5-May-2010
Research & Development Pharmaceutical

Quinolone antibiotics prevent the bacteria’s DNA from unwinding, thus stopping them replicating

Quinolone antibiotics first reached the market in the 1960s, and work by preventing the bacteria’s DNA from unwinding, and thus stopping them replicating. The key target is the enzyme topoisomerase II, or DNA gyrase, and more recently introduced quinolone antibiotics such as ciprofloxacin and moxifloxacin have increased activity againt this enzyme.

However, there is a growing incidence of resistance against these key antibacterial agents; notably, the majority of strains of methicillin-resistant Streptococcus aureus are resistant to marketed quinolones. There is also significant resistance from several other bacteria, including Streptococcus pneumoniae and Pneumococcus influenzae. Therefore, there is a need for analogues of these otherwise potent antibiotics that retain activity against these resistant strains.

One such molecule that is under development is TaiGen Biotechnology’s nemonoxacin, which licensed the non-fluorinated quinolone drug from Procter & Gamble for development in a variety of Asian markets.1 It shows good activity against MRSA, multidrug resistant S. pneumoniae, vancomycin-resistant S. aureus and a wide range of other bacteria, both Gram positive and Gram negative.

Results of two Phase I trials have recently been published. In one 56 healthy subjects were enrolled in a double blind, ascending single dose study and randomised to one of seven dose cohorts.2 In each of these, two subjects were given placebo, and six single oral doses of between 25 and 1500mg nemonoxacin. It was well tolerated up to the maximum dose, and no serious adverse events were seen, with the most common being contact dermatitis, erythema and pruritis. Its peak time was 1 to 2 hours, and half-life between 9 and 16 hours.

In the second, 46 healthy volunteers were given oral doses of 75 to 1000mg once a day for 10 days.3 It was generally safe and well tolerated, with the most common side-effects being headache, contact dermatitis and rash. It was rapidly absorbed within 2 hours of dosing, and a steady state was achieved after 3 days in most subjects. The pharmacokinetics were affected by food, causing a decrease in plasma concentration, but free drug levels were good whether the subjects were fasting or fed.

A randomised, double blind Phase II trial has also been reported.4 Its efficacy was compared with that of levofloxacin in patients with community acquired pneumonia at once daily doses of 500 or 750mg for seven days. The most common pathogens involved were H. influenzae, S. pneumoniae and S. aureus. Clinical cure rates were 92% for the higher dose of nemonoxacin, 88% for the lower dose, and 94% for 500mg of levofloxacin. In addition, the company has recently announced by press release that it had shown promising clinical efficacy and good tolerability in a Phase II trial in patients with diabetic foot infections.

References

1. G.G. Zhanel et al. 48th Ann. Intersci. Conf. Antimicrob. Agents Chemother. Infect. Dis. Soc. Am. Ann. Meet. (Oct 25-28, Washington DC), 2008, Abst F1-2057; N. Laing et al. ibid. Abst. C1-1957
2. L. Lin et al. Antimicrob Agents Chemother. 2010, 54, 405
3. D.T. Chang et al. Antimicrob Agents Chemother. 2010, 54, 411
4. D.J. van Rensburg et al. 48th Ann. Intersci. Conf. Antimicrob. Agents Chemother. Infect. Dis. Soc. Am. Ann. Meet. (Oct 25-28, Washington DC), 2008, Abst. L-678
See more

You may also like

Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Read more
Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea

Trending Articles

  1. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  2. Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
  3. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  4. Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
  5. Nanologica secures first insulin purification order in China The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Intertronics releases white paper on process validation for medical device bonding

The new guidance helps manufacturers cut costs, save time and ensure ISO and FDA compliance by designing out variability and improving process reliability from the start
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part II)

Part II of this article focuses on defining what “good” looks like in biorepository infrastructure, validation and documentation, providing practical guidance to create resilient, compliant storage solutions that underpin successful oncology research
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Finance

Nanologica secures first insulin purification order in China

The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
Subscribe now